Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 9;23(19):12011.
doi: 10.3390/ijms231912011.

The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review

Affiliations
Review

The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review

Ioana Bratoiu et al. Int J Mol Sci. .

Abstract

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by heterogeneous changes involving numerous organs and systems. The currently available data indicate that muscle injury (both smooth and striated muscles) is widespread and leads to significant morbidity, either directly or indirectly. From the consequences of smooth muscle involvement in the tunica media of blood vessels or at the level of the digestive tract, to skeletal myopathy (which may be interpreted strictly in the context of SSc, or as an overlap with idiopathic inflammatory myopathies), muscular injury in scleroderma translates to a number of notable clinical manifestations. Heart involvement in SSc is heterogenous depending on the definition used in the various studies. The majority of SSc patients experience a silent form of cardiac disease. The present review summarizes certain important features of myocardial, as well as smooth and skeletal muscle involvement in SSc. Further research is needed to fully describe and understand the pathogenic pathways and the implications of muscle involvement in scleroderma.

Keywords: myositis; sarcopenia; skeletal muscle; smooth muscle; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Denton C., Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. doi: 10.1016/S0140-6736(17)30933-9. - DOI - PubMed
    1. Varga J., Trojanowska M., Kuwana M. Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities. J. Scleroderma Relat. Disord. 2017;2:137–152. doi: 10.5301/jsrd.5000249. - DOI
    1. Ferreli C., Gasparini G., Parodi A., Cozzani E., Rongioletti F., Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: A Comprehensive Review. Clin. Rev. Allergy Immunol. 2017;53:306–336. doi: 10.1007/s12016-017-8625-4. - DOI - PubMed
    1. Di Battista M., Barsotti S., Orlandi M., Lepri G., Codullo V., Della Rossa A., Guiducci S., Del Galdo F. One year in review 2021: Systemic sclerosis. Clin. Exp. Rheumatol. 2021;39((Suppl. 131)):3–12. doi: 10.55563/clinexprheumatol/izadb8. - DOI - PubMed
    1. Cutolo M., Soldano S., Smith V. Pathophysiology of systemic sclerosis: Current understanding and new insights. Expert Rev. Clin. Immunol. 2019;15:753–764. doi: 10.1080/1744666X.2019.1614915. - DOI - PubMed